SCHEMBL4871193

SCHEMBL4871193

CCC(NC(=O)N1CCCCc2cc(F)ccc21)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 6/20 0.49
FPR2 P25090 6/20 0.49
POLB P06746 3/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 1/20 0.48
BRD4 O60885 1/20 0.44
CREBBP Q92793 1/20 0.44
NOTUM Q6P988 1/20 0.44
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
THRB P10828 1/20 0.42
IDO1 P14902 1/20 0.42
KCNQ2 O43526 1/20 0.41
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4870873 0.90 POLB (0.61) FPR1FPR2POLBLMNAMAPT
SCHEMBL4868688 0.83 LMNA (0.53) POLBLMNAMAPTTHRB
SCHEMBL4865684 0.78 PDK1 (0.56) POLBLMNAMAPTNOTUMHDAC1
SCHEMBL23494513 0.78 PDK1 (0.45) FPR1FPR2LMNAMAPTHDAC1
SCHEMBL23494514 0.78 PDK1 (0.45) FPR1FPR2LMNAMAPTHDAC1
SCHEMBL6677985 0.77 MAPT (0.51) POLBLMNAMAPTNOTUMTHRB
SCHEMBL4869665 0.77 HDAC1 (0.49) POLBLMNAMAPTNOTUMHDAC1
SCHEMBL4860668 0.77 TP53 (0.58) POLBLMNAMAPTNOTUMHDAC1
SCHEMBL4871838 0.77 TP53 (0.58) POLBLMNAMAPTNOTUMHDAC1
SCHEMBL4869687 0.76 PDK1 (0.53) POLBLMNAMAPTTHRBIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US claimed
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 FPR1 963/4885FPR2 1287/4885POLB 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.